CAPRICOR THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
CAPR$9.85+9.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
We do not own any real property. Our primary operations are conducted at the leased facilities summarized in the below table. We believe our facilities are adequate and suitable for our current needs and that we will be able to obtain new or additional leased space in the future, if necessary.
| | | | |
|---|---|---|---|
| Location of Property | Lease Expiration Date (1) | Purpose | Square Footage (approximate) |
| 10865 Road to the Cure, Suite 150, San Diego, California | September 30, 2026 | Corporate Headquarters: Laboratory, manufacturing and office space | 12,161 |
| 10865 Road to the Cure, Room 7, San Diego, California | October 31, 2024 | Laboratory space | 234 |
| 8840 Wilshire Blvd., 2nd Floor, Beverly Hills, California | Month-to-Month, terminable on 90-day notice | Office space | 1,627 |
| 8700 Beverly Blvd., Davis Building, Los Angeles, California | July 31, 2026 | Laboratory, manufacturing and office space | 1,892 |
| (1) | Certain leases have specific options for potential renewal or extensions. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.